Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects

Xspray Pharma publ AB

28/04/2026 07:25

Corrects table to show Pretax loss was SEK 35.38 mln, not 35,380

Overview

Sweden pharma firm's Q1 revenue unchanged at SEK 0, pretax loss narrows yr/yr

Company completed oversubscribed rights issue, raising SEK 113 mln before transaction costs

FDA accepted Dasynoc resubmission for review, PDUFA date set for August 2026

Outlook

Company expects FDA decision on Dasynoc by August 25, 2026

Nilopki FDA decision expected by June 18, 2026, with U.S. launch planned in H2 2026

Company may seek additional financing to complete double launch and reach cash-flow positivity

Result Drivers

REGULATORY PROGRESS - FDA accepted Dasynoc resubmission for review and set PDUFA date for August 2026

CLINICAL NEED - Co highlighted strong physician engagement and unmet need for Dasynoc, especially for CML patients using PPIs

CAPITAL RAISE - Oversubscribed rights issue secured SEK 113 mln to support commercial launch preparations

Company press release: ID:nMFNb1mrH0

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
SEK 0
Q1 EPS before dilution
-SEK 0.85
Q1 Pretax Profit
-SEK 35.38 mln


Analyst Coverage

Wall Street's median 12-month price target for Xspray Pharma publ AB is SEK58.35, about 116.9% above its April 27 closing price of SEK26.90

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)